VSTM - Verastem Inc Stock Price, Fair Value and News

$10.04+0.26 (+2.66%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VSTM Price Action

Last 7 days

-5.5%

Last 30 days

1.4%

Last 90 days

-4.9%

Trailing 12 Months

86.3%

VSTM RSI Chart

VSTM Valuation

Market Cap

670.4M

Price/Earnings (Trailing)

-2.78

Price/Sales (Trailing)

50.11

EV/EBITDA

-3.2

Price/Free Cashflow

-5.05

VSTM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VSTM Fundamentals

VSTM Revenue

Revenue (TTM)

13.4M

Rev. Growth (Yr)

-78.63%

Rev. Growth (Qtr)

426.06%

VSTM Earnings

Earnings (TTM)

-241.1M

Earnings Growth (Yr)

-311.06%

Earnings Growth (Qtr)

-279.88%

VSTM Profitability

EBT Margin

-975.05%

Return on Equity

1.6K%

Return on Assets

-136.33%

Free Cashflow Yield

-19.79%

VSTM Investor Care

Shares Dilution (1Y)

50.04%

Diluted EPS (TTM)

-4.45

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	12.1M	13.4M	0
2024	0	10.0M	10.0M	10.0M
2022	2.4M	2.8M	3.1M	2.6M
2021	66.9M	45.3M	23.7M	2.1M
2020	20.8M	22.0M	91.6M	88.5M
2019	24.4M	22.1M	19.8M	17.5M
2018	0	0	0	26.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Verastem Inc

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

CEO	Mr. Daniel W. Paterson
WEBSITE	verastem.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	57

Verastem Inc Frequently Asked Questions

What is the ticker symbol for Verastem Inc? What does VSTM stand for in stocks?

VSTM is the stock ticker symbol of Verastem Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verastem Inc (VSTM)?

As of Wed Dec 03 2025, market cap of Verastem Inc is 670.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VSTM stock?

You can check VSTM's fair value in chart for subscribers.

Is Verastem Inc a good stock to buy?

The fair value guage provides a quick view whether VSTM is over valued or under valued. Whether Verastem Inc is cheap or expensive depends on the assumptions which impact Verastem Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VSTM.

What is Verastem Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, VSTM's PE ratio (Price to Earnings) is -2.78 and Price to Sales (PS) ratio is 50.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VSTM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Verastem Inc's stock?

In the past 10 years, Verastem Inc has provided -0.088 (multiply by 100 for percentage) rate of return.